Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Direct Correlation between Age at Diagnosis and Severity of Nephropathy in Fabry Disease Patients.

Jaurretche SPA, Antongiovanni N, Perretta F.

Indian J Nephrol. 2019 Nov-Dec;29(6):398-401. doi: 10.4103/ijn.IJN_167_18.

2.

Variables Associated with a Urinary MicroRNAs Excretion Profile Indicative of Renal Fibrosis in Fabry Disease Patients.

Jaurretche S, Perez G, Antongiovanni N, Perretta F, Venera G.

Int J Chronic Dis. 2019 Jun 24;2019:4027606. doi: 10.1155/2019/4027606. eCollection 2019.

3.

Knowledge and risk perceptions of foodborne disease by consumers and food handlers at restaurants with different food safety profiles.

de Andrade ML, Rodrigues RR, Antongiovanni N, da Cunha DT.

Food Res Int. 2019 Jul;121:845-853. doi: 10.1016/j.foodres.2019.01.006. Epub 2019 Jan 6.

PMID:
31108817
4.

Fabry nephropathy. Role of nephrologist and clinical variables associated with the diagnosis.

Jaurretche S, Antongiovanni N, Perretta F.

Nefrologia. 2019 May - Jun;39(3):294-300. doi: 10.1016/j.nefro.2018.10.017. Epub 2019 Mar 16. English, Spanish.

5.

Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?

Politei J, Alberton V, Amoreo O, Antongiovanni N, Arán MN, Barán M, Cabrera G, Di Pietrantonio S, Durand C, Fainboim A, Frabasil J, Pizarro FG, Iotti R, Liern M, Perretta F, Ripeau D, Toniolo F, Trimarchi H, Rivas DV, Wallace E, Schenone AB.

Pediatr Nephrol. 2018 Nov;33(11):2095-2101. doi: 10.1007/s00467-018-4006-3. Epub 2018 Jul 9.

PMID:
29987457
6.

Major Organic Involvement in Women with Fabry Disease in Argentina.

Perretta F, Antongiovanni N, Jaurretche S.

ScientificWorldJournal. 2018 May 21;2018:6515613. doi: 10.1155/2018/6515613. eCollection 2018.

7.

Early Renal Involvement in a Girl with Classic Fabry Disease.

Perretta F, Antongiovanni N, Jaurretche S.

Case Rep Nephrol. 2017;2017:9543079. doi: 10.1155/2017/9543079. Epub 2017 Oct 1.

8.

Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America.

Ripeau D, Amartino H, Cedrolla M, Urtiaga L, Urdaneta B, Cano M, Valdez R, Antongiovanni N, Masllorens F.

Medicina (B Aires). 2017;77(3):173-179.

9.

[Guidelines for diagnosis, monitoring and treatment of Fabry disease].

Consenso de Médicos de AADELFA y GADYTEF, Neumann P, Antongiovanni N, Fainboim A, Kisinovsky I, Amartino H, Cabrera G, Carmona S, Ceci R, Cicerán A, Choua M, Doxastakis G, De Maio S, Ebner R, Escobar AM, Ferrari G, Forrester M, Guelbert N, Luna P, Marchesoni C, Masllorens F, Politei J, Reisin R, Ripeau D, Rozenfeld P, Serebrinsky G, Tarabuso AL, Trípoli J.

Medicina (B Aires). 2013;73(5):482-94. Spanish.

10.

Fabry disease in Argentina: an evaluation of patients enrolled in the Fabry Registry.

Politei JM, Cabrera G, Amartino H, Valdez R, Masllorens F, Ripeau D, Antongiovanni N, Soliani A, Luna P, Cedrolla M, Fernandez S, Fainboim A.

Int J Clin Pract. 2013 Jan;67(1):66-72. doi: 10.1111/ijcp.12081.

PMID:
23241050

Supplemental Content

Loading ...
Support Center